Compare TWIN & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TWIN | TVGN |
|---|---|---|
| Founded | 1918 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Blank Checks |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 21.3M |
| IPO Year | 1994 | 2021 |
| Metric | TWIN | TVGN |
|---|---|---|
| Price | $24.17 | $6.57 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 76.2K | 11.7K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $340,738,000.00 | N/A |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $13.97 | ★ N/A |
| Revenue Growth | ★ 15.45 | N/A |
| 52 Week Low | $8.03 | $0.14 |
| 52 Week High | $25.00 | $12.03 |
| Indicator | TWIN | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.77 | 53.59 |
| Support Level | $14.75 | $6.33 |
| Resistance Level | $24.28 | $7.42 |
| Average True Range (ATR) | 0.98 | 0.69 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 71.47 | 70.40 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.